Ripretinib

DRUG8 trials

Conditions

GISTGIST - Gastrointestinal Stromal TumorGastrointestinal Stromal Tumor(GIST)Gastrointestinal Stromal Tumors

Phase 1

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

CompletedNCT04530981

Deciphera Pharmaceuticals, LLCGIST - Gastrointestinal Stromal Tumor

Start: 2021-09-22End: 2024-07-29Updated: 2024-09-19

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

WithdrawnNCT05080621

Deciphera Pharmaceuticals, LLCGastrointestinal Stromal Tumors

Start: 2021-11-30End: 2027-05-31Updated: 2022-01-05

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

RecruitingNCT05957367

Deciphera Pharmaceuticals, LLCGIST

Start: 2023-09-28End: 2029-03-01Target: 94Updated: 2026-07-23

Phase 2

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

CompletedNCT04633122

Zai Lab (Shanghai) Co., Ltd.Gastrointestinal Stromal Tumor(GIST)

Start: 2020-11-25End: 2022-07-20Updated: 2026-04-03

Phase 3

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruitingNCT03673501

Deciphera Pharmaceuticals, LLCGastrointestinal Stromal Tumors

Start: 2019-02-08End: 2026-12-01Updated: 2026-02-05

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Active, not recruitingNCT05734105

Deciphera Pharmaceuticals, LLCGIST

Start: 2023-12-13End: 2028-12-31Target: 54Updated: 2025-12-17

Unknown Phase

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

NCT04148092

Deciphera Pharmaceuticals, LLCGIST - Gastrointestinal Stromal Tumor

Updated: 2020-05-29

Ripretinib (QINLOCK®) According to Current SmPC

CompletedNCT06619275

iOMEDICO AGGIST - Gastrointestinal Stromal Tumor

Start: 2024-10-17End: 2025-09-15Updated: 2025-12-05

Journal of Clinical Oncology2026-05-28

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Journal of Clinical Oncology2025-05-23

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.

Journal of Clinical Oncology2025-01-271 citations

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.

2025-01-269 citations

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Future Oncology2024-08-2612 citations

DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.

Journal of Clinical Oncology2024-06-011 citations

62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE

ESMO Open2024-03-01

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

Journal of Clinical Oncology2024-01-202 citations

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Nature Medicine2024-01-0546 citations

INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.

Journal of Clinical Oncology2023-06-016 citations

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.

Journal of Clinical Oncology2023-06-012 citations

Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Journal of Clinical Oncology2023-06-011 citations

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.

Journal of Clinical Oncology2023-01-3015 citations

Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, open-label study in China.

Journal of Clinical Oncology2023-01-243 citations

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology2022-08-10102 citations

Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.

Journal of Clinical Oncology2022-06-013 citations

INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib

Journal of Clinical Oncology2022-01-2518 citations

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Journal of Clinical Oncology2020-08-1788 citations

Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)

Molecular Cancer Therapeutics2019-12-013 citations

1 more papers not shown